Trial reportFrontiers in endocrinology2026
Outcomes of methylprednisolone as an adjunct to endovascular therapy in patients with diabetes and admission hyperglycemia.
Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to evaluate the effect of methylprednisolone as adjunctive treatment to endovascular therapy (EVT) in patients with and without diabetes, as well as in patients with and without admission hyperglycemia. Methods: This study was a secondary analysis of the MARVEL trial. The primary outcome was the ordinal modified Rankin Scale (mRS) score at 90 days. Secondary outcomes included mRS score of 0-3, 0-2, 0-1 at 90 days. Safety outcomes included mortality within 90 days, symptomatic intracranial hemorrhage (sICH) and any ICH within 48 hours. Results: Among 1,678 patients from the MARVEL trial, 321 had history of diabetes. In patients with diabetes, methylprednisolone was not associated with improved 90-day mRS [common odds radio (cOR), 1.07 (0.81-1.40), P = 0.640] but was associated with more any ICH within 48 hours [OR, 1.63 (1.17-2.26), P = 0.004]. In patients without diabetes, methylprednisolone was associated with better 90-day mRS [cOR, 1.16 (1.02-1.33), P = 0.026] and lower 90-day mortality [OR, 0.74 (0.62-0.88), P = 0.001]. A significant treatment-by-diabetes-history interaction was observed only for any ICH within 48 hours (P for interaction = 0.036). Among 1,470 patients stratified by admission hyperglycemia, methylprednisolone was not associated with improved 90-day mRS in either subgroup. Conclusion: The glycemia status-by-treatment interaction was not significant. A benefit trend was observed with adjunctive methylprednisolone in patients without diabetes. However, adjunctive use of methylprednisolone in patients with diabetes may be with a higher risk of any intracranial hemorrhage. Admission hyperglycemia status did not significantly modify the effectiveness or safety of methylprednisolone. These findings warrant validation in further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.